Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease

NCT ID: NCT06844864

Last Updated: 2025-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-01

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Enquire involvement of trained immunity in the pathogenesis of IgG4RD

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Enquire involvement of trained immunity in the pathogenesis of IgG4RD using primary macrophages and co-cultures with patient derived fibroblasts. The investigators will first assess whether macrophages from patients are trained compared to macrophages of healthy controls and then challenge them with IgG from IgG4RD patients to evaluate the functional effects on cultivated fibroblasts.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IgG4 Related Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients:

* Adult subjects \> or = 18 years of age
* Subjects capable of providing informed consent
* Active IgG4-RD based on the IgG4-related disease activity index
* Fulfillment of the 2019 ACR/EULAR Classification Criteria for IgG4RD

Healthy Controls:

* Adult subjects \> or = 18 years of age
* Subjects capable of providing informed consent

Exclusion Criteria

Patients and healthy controls:

* Subjects \< 18 years of age
* Pregnant women
* Comorbidities (other ongoing active autoimmune diseases, ongoing cancer, ongoing infections)
* Ongoing immunosuppressive therapy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IRCCS San Raffaele

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Emanuel Della Torre

Principal Investigator, Assistant Professor of Internal Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ospedale San Raffaele

Milan, MI, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022FH5R92

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2022FH5R92

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.